Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

Annals of Neurology

Volumn 42, Issue 3, 1997, Pages 313-318

  Smith, Derek R ^a,b   Balashov, Konstantin E ^a   Hafler, David A ^a   Khoury, Samia J ^a   Weiner, Howard L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD3;

ADULT; ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSIS; DISEASE ASSOCIATION; EOSINOPHILIA; ETIOLOGY; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; INTERFERON PRODUCTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ADULT; ALKYLATING AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-BETA; INTERLEUKIN-4; MALE; METHOTREXATE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS;

EID: 0030767497     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420307     Document Type: Article

References (34)

1. Hafler DA, Weiner HL. Immunologie mechanisms and therapy in multiple sclerosis. Immunol Rev 1995:144:75-107
2. Beck J, Rondot P, Catinot L, et al. Increased production of intetferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323
3. Panitch HS, Hirsch RL, Haley AS, et al. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987;1:893-895
4. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994;180:1961-1966
5. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Thl/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995:80:707-718
6. Piccinni M, Giudizi M, Biagiotti R, et al. Progesterone favors the development of human T helper cells producing Th2 type cytokines and promotes both IL-4 production and membrane CD30 expression in established Thl cell clones. J Immunol 1995:155:128-133
7. McCune W, Golbus J, Zeldes W, et al. Clinical and immunologie effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988:318:1423-1431
8. Gourley M, Austin HR, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized controlled trial. Ann Int Med 1996:125:549-557
9. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993:43:910-918
10. Group. TCCMSS. The Canadian Cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991:337:442-446
11. Goodkin D, Rudick R, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995:37: 30-40
12. Sipe JC, Romine JB, Koziqi JA, et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994:344:9-13
13. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993:239:1764-1769
14. IFNβ Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995:45:1277-1285
15. Jacobs L. Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann Neurol 1996:39:285294
16. Balashov K, Smith D, Hafler D, et al. Increased IL-12 production in progressive MS: induction by activated CD4 T cells via CD40 ligand. Proc Natl Acad Sei USA 1997:94:599-603
17. 16a. Rudick RA, RansohofF RM, Peppier R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996:40:618-627
18. Schleimer R, Bochner B. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 1994:94:1202-1213
19. Cogan E, Schandene L, Crusiaux A, et al. Clonal proliferation of type 2 helper T cells in a man with hypereosinophilic syndrome. N Engl J Med 1994:330:535-538
20. Caterino-de-Araujo A. HIV-1 infection and eosinophilia. Immunol Today 1994;15:498-499
21. Vadas M. Cyclophosphamide pretreatment induces eosinophilia to nonparasite antigens. J Immunol 1981;127:2083-2086
22. Mathie I, Sewell H, Thomson A. Generation of large granular lymphocytes and lymphocyte subset changes linked with Cyclophosphamide induced eosinophilia in rats-and the effects of cyclosporin. Scand J Immunol 1987;26:417-425
23. Marshall J, Wen Y, Abrams J, et al. In vitro synthesis of IL-4 by human CD4+ T cells requires repeated antigenic stimulation. Cell Immunol 1993:152:18-34
24. + T lymphocytes. J Immunol 1995:155:111-117
25. Yoshimoto T, Paul W. CD4 pos, NK1.1 pos T cells promptly produce IL-4 in response to in vivo challenge with anti-CD3. J Exp Med 1994:179:1285-1295
26. Sumida T, Sakamoto A, Murata H, et al. Selective reduction of T cells bearing invariant Valpha24JalphaQ antigen receptor in patients with systemic sclerosis. J Exp Med 1995:182:11631168
27. Scheinman R, Cogswell P, Lofquist A, et al. Role of iKBot in mediation of immunosuppression by glucocorticoids. Science 1995:270:283-286
28. Zubiaga A, Munoz E, Huber B. IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid induced apoptosis. J Immunol 1992:149:107-112
29. Cupps T, Edgar L, Fauci A. Suppression of human B lymphocyte function by Cyclophosphamide. J Immunol 1985:128: 2453-2457
30. Hafler DA, Orav EJ, Gertz R, et al. Immunologie effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol 1991:32:149-158
31. Lodge P, Allegretta M, Steinman L, et al. Myelin basic protein peptide specificity and T cell receptor gene usage of HPRT mutant T cell clones in patients with multiple sclerosis. Ann Neurol 1994:36:734-740
32. Sriram S. Longitudinal study of frequency of HPRT mutant T cells in patients with multiple sclerosis. Neurology 1994;44: 311-315
33. Karussis DM, Meiner Z, Lehmann D, et al. Treatment of secondary progressive MS with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly MRI evaluation. Neurology 1996:47:341-346
34. IFNβ Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993:43:655-661